BTX 1050
Alternative Names: BTX-1050Latest Information Update: 01 Apr 2021
At a glance
- Originator Hebrew University of Jerusalem
- Developer BioTheryX
- Class Antineoplastics; Small molecules
- Mechanism of Action IKZF2 protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer